Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

InDex Pharmaceuticals - Update on recently announced results of PK-study with cobitolimod

By HC Andersen Capital
Flerie

Meet and ask questions to CEO Jenny Sundqvist and CDO Eva Arlander from InDex Pharmaceuticals Tuesday the 28th of March at 3.00 PM.

CEO Jenny Sundqvist will give a recap of the company and its on-going phase III program and CDO Eva Arlander will give an update on the recently announced results of the PK-study with cobitolimod.

InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.

Disclaimer: HC Andersen Capital receives payment from InDex Pharmaceuticals for a DigitalIR/Corporate Visibility agreement./ Claus Thestrup 10.10 AM 22-03-2023.

Recent videos

Tokmanni Q4’25: Dollarstore’s turnaround is stalling
LIVE
2026-03-12 12:02 Tokmanni Group
Multitude, Webcast, Q4'25
2026-03-12 10:00 Multitude
Rapala VMC Oyj, Audiocast, Q4'25
2026-03-12 10:00 Rapala VMC
Rusta, Webcast, Q3'25/26
2026-03-12 09:00 Rusta
Easor, Webcast, Q4'25
2026-03-11 11:30 Easor
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.